Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) – Ascendiant Capital Markets upped their Q3 2026 EPS estimates for Atossa Genetics in a research report issued on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.78) per share for the quarter, up from their prior estimate of ($1.10). The consensus estimate for Atossa Genetics’ current full-year earnings is ($3.75) per share. Ascendiant Capital Markets also issued estimates for Atossa Genetics’ Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.56) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.83) EPS, Q4 2027 earnings at ($0.83) EPS and FY2027 earnings at ($3.30) EPS.
Atossa Genetics (NASDAQ:ATOS – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.07.
Atossa Genetics Stock Up 0.4%
ATOS opened at $2.46 on Tuesday. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35. The company has a fifty day simple moving average of $2.39 and a 200 day simple moving average of $3.48. The stock has a market cap of $24.55 million, a P/E ratio of -0.79 and a beta of 1.27.
Institutional Investors Weigh In On Atossa Genetics
An institutional investor recently bought a new position in Atossa Genetics stock. State Street Corp bought a new position in Atossa Genetics Inc. (NASDAQ:ATOS – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned 0.40% of Atossa Genetics at the end of the most recent quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.
About Atossa Genetics
Atossa Genetics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer. The company’s research is centered on precision medicines intended to address unmet needs in breast cancer treatment and prevention.
Atossa’s leading development program is oral endoxifen, an active metabolite of tamoxifen and a selective estrogen receptor modulator. The company is evaluating endoxifen in clinical studies involving hormone receptor-positive breast cancer, including settings before surgery and in patients who may benefit from reducing tumor activity or breast cancer risk.
Founded in 2009 and headquartered in Seattle, Washington, Atossa initially pursued diagnostic products for breast health before concentrating its business on therapeutic development.
Featured Articles
- Five stocks we like better than Atossa Genetics
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
